ICVX Icosavax Inc

By Ian Walker

AstraZeneca said it would buy U.S.-based clinical-stage biopharmaceutical company Icosavax for up to $1.1 billion in a deal that expands its vaccines and immune therapies late-stage pipeline.

The pharmaceutical giant is offering $15 for each Icosavax share held, a 43% premium to its closing market price of $10.49 on Monday.

An extra $5.00 a share in cash could be paid depending upon certain regulatory and sales milestones being met.

Icosavax has a protein virus-like particle platform technology used to develop vaccines against infectious diseases. Its initial focus is on life-threatening respiratory diseases, with a vision for combination and pan-respiratory vaccines.

"With the addition of Icosavax's Phase 3-ready lead asset to our late-stage pipeline, we will have a differentiated, advanced investigational vaccine, and a platform for further development of combination vaccines against respiratory viruses," said AstraZeneca's executive vice president, Vaccines & Immune Therapies, Iskra Reic.

AstraZeneca said it expects the acquisition to close in the first quarter of 2024.

Write to Ian Walker at ian.walker@wsj.com

(END) Dow Jones Newswires

December 12, 2023 02:47 ET (07:47 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.